Treats serious or severe infections caused by susceptible strains of…. ANDA 205694, held by Gland. Vancomycin Hydrochloride.
As of Nov 16, 2026, ANDA 205694 (Vancomycin Hydrochloride), held by Gland, was first approved by FDA on Jan 21, 2016, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Vancomycin Hydrochloride for Injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 21, 2016 | Original application | Approved | None posted |
| Vancomycin HydrochlorideEQ 500MG BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Rx |
| Vancomycin HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Rx |
| Vancomycin HydrochlorideEQ 5GM BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Rx |
| Vancomycin HydrochlorideEQ 10GM BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Rx |
| Jun 6, 2023 | Supplement 11Manufacturing | Approved | None posted |
| Jul 28, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 19, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 19, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 21, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters